Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol

Ontaneda, Daniel, Tallantyre, Emma C., Raza, Praneeta C., Planchon, Sarah M., Nakamura, Kunio, Miller, Deborah, Hersh, Carrie, Craner, Mathew, Bale, Clare, Chaudhry, Burhan, Gunzler, Douglas D., Love, Thomas E., Gerry, Stephen, Coles, Alasdair, Cohen, Jeffrey A. and Evangelou, Nikos 2020. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials 95 10.1016/j.cct.2020.106009 Item availability restricted.

PDF - Accepted Post-Print Version Restricted to Repository staff only until 19 April 2021 due to copyright restrictions. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (387kB)

Abstract

Multiple Sclerosis (MS) is a common cause of neurological disability among young adults and has a high economic burden. Currently there are 18 disease modifying agents for relapsing MS, which were tested in clinical trials versus placebo or an active comparator in a pairwise manner. However, there is currently no consensus on the fundamental principles of treatment approach and initial therapy selection. These factors result in variable use of disease modifying therapies. Here we describe the study protocol for Determining the Effectiveness of earLy Intensive Versus Escalation approaches for the Treatment of Relapsing-remitting Multiple Sclerosis (DELIVER-MS). The main objective of the study is to determine whether an early highly effective treatment approach, defined as use of one of four monoclonal antibodies as initial therapy, is more effective than an escalation treatment approach (any other approved medication as initial therapy with subsequent escalation to higher efficacy treatments guided by radiological and clinical evaluation). The primary endpoint of the study is reduction in normalized brain volume loss from baseline visit to month 36 visit using MRI. Brain volume loss was selected as the best short-term predictor of long-term clinical disability. A total of 400 participants will be randomized 1:1 using minimization to account for age and sex by site, and 400 will be enrolled into a parallel observational cohort. The study results will help guide overall treatment philosophy and will have important implications for patient choice, clinical practice, and treatment access.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Neuroscience and Mental Health Research Institute (NMHRI) Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	Elsevier
ISSN:	1551-7144
Date of First Compliant Deposit:	20 April 2020
Date of Acceptance:	14 April 2020
Last Modified:	18 Jan 2021 21:25
URI:	http://orca.cf.ac.uk/id/eprint/131100

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item